HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
Last updated: 2026-11-19 12:04:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rein Therapeutics, Inc. (RNTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.36, with a market capitalization of $30.75M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.28 to $2.10. This page covers its latest market performance, valuation, price trends and company information.
$30.75M | |
$0.36 | |
$0.36 | |
$0.36 | |
$0.36 | |
1.00 | |
568.35K | |
-- | |
$2.10 | |
$0.28 | |
-- | |
2026-09-30 |
Rein Therapeutics, Inc. (RNTX) is trading at $0.36 in pre-market trading as of 2026-11-19 11:20:00, up 1.32% ($0.00) from the previous close of $0.36
Pre-market trading shows how investors are pricing RNTX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Rein Therapeutics, Inc. (RNTX) moved from $0.59 to $0.36, representing a decline of 38.98% ($0.23).
The stock traded between $0.28 and $0.63 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.92 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4.2%
RNTX is currently trading at $0.36, placing it 4.2% of the way from its 52-week low of $0.28 to its 52-week high of $2.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Rein Therapeutics, Inc. and RNTX stock.
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
Gainers Akanda (NASDAQ:AKAN) stock rose 42.6% to $1.94 during Monday's regular session. The market value of their outstanding shares is at $3.5 million. CEL-SCI (AMEX:CVM) shares increased by 30.46% to $1.67. The
33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at Week 12From baseline, change in FVC ranged from an improvement of 338 ml to a decline of 349 ml at Week 12Low
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 40 percent. This is a 71.43 percent increase over losses of $(0.21) per share from
Eligible investors can buy real shares of Rein Therapeutics, Inc. (RNTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RNTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RNTX shares and USD.
RNTX Shares to USD
1.00 RNTX shares = 0.36 USD
Calculations are estimates based on the latest available price and are for reference only.